FAPA On It’s 30th Anniversary
The day was filled with informative talks, including an introduction from Prof. Dr Eric Van Cutsem for the Dutch-speaking audience of patients, out...
Imfinzi & Imjudo Immunotherapy Drug Combinations Approved in the EU for the Treatment of Advanced Liver Cancer
The combination of durvalumab (Imfinzi) and tremelimumab (Imjudo) immunotherapies has been approved by the European Commission (EC) for the first-l...
Zolbetuximab Plus Chemotherapy Extends Overall Survival for Patients with Advanced or Metastatic Gastric & Gastro-oesophageal Junction Adenocarcinoma
The Annual American Society of Clinical Oncologists Gastrointestinal Cancers Symposium (ASCO GI) kicked off the year with lots of new data in the f...
First Immunotherapy Drug Durvalumab Plus Chemotherapy Approved in Europe for Advanced Biliary Cancer
On 21 December the European Commission (EC) approved the use of durvalumab (Imfinzi ®) plus chemotherapy (gemcitabine plus cisplatin) as the first...
Trastuzumab Deruxtecan Approved as Second-line Treatment in Europe For Patients With HER2-positive Advanced Gastric Cancer
On December 19th the European Commission (EC) approved the use of trastuzumab deruxtecan (Enhertu ®) plus chemotherapy (gemcitabine plus cisplatin...
Nutrition Position Paper
Nutritional intervention is essential to cancer treatments. It can reduce hospitalisation length and treatment-related toxicity while improving nut...
Member Organisation Update
News From The North, PALEMA’s Tireless Efforts During The Months of October and November
...
National Cancer Center Japan Asks for Your Support on a Project to Impact Patient Engagement
Would you like to know how and where patient engagement is happening in R&D? Would you like to see an objective comparison between Europe and J...
We Have a Winner! Results of the Wolfram Nolte Memorial Award
We are pleased to announce the 2021 Winner of the Wolfram Nolte Memorial Award – EuropaColon Polska!
...